Cabot Giese Neg
| Tournament | Round | Opponent | Judge | Cites | Round Report | Open Source | Edit/Delete |
|---|---|---|---|---|---|---|---|
| Bentonville Tigers Eye | 2 | Alexis Childs | Joel Brown |
|
|
| |
| Little Rock Central | 1 | JPG Dozda | Adicherla, Shreyas |
|
|
| |
| Little Rock Central | 3 | JPG Lagneaux | Breckenridge, Andrea |
|
|
| |
| The Ed Long Invitational at The Hockaday School | 1 | Coppell NP | Berdugo, Erick |
|
|
|
| Tournament | Round | Report |
|---|---|---|
| Bentonville Tigers Eye | 2 | Opponent: Alexis Childs | Judge: Joel Brown 1AC 1NC Won't be posting cites as I have identical sites to those used in previous rounds |
| Little Rock Central | 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas 1AC 1NC |
| Little Rock Central | 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea 1AC 1NC |
| The Ed Long Invitational at The Hockaday School | 1 | Opponent: Coppell NP | Judge: Berdugo, Erick 1AC 1NC |
To modify or delete round reports, edit the associated round.
Cites
| Entry | Date |
|---|---|
Counterfeit DrugsTournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas In 2012 a counterfeit of the cancer drug Avastin was found in the United States, entering the country through a complex worldwide “grey market” of suppliers. The counterfeit drugs traced a path through Turkey, Switzerland, the United Kingdom, and finally the United States,ending up in the hands of cancer patients fighting for their lives. Unbeknownst to the medical professionals prescribing what they thought were lifesaving prescriptions, the drugs were devoid of the active ingredient needed to reduce the growth of patients’ tumors.1The World Health Organization estimates that there are over 1 million deaths annually from counterfeit and substandard drugs, causing $21 billion global financial impacts. 2For the past 10 months, recalls of blood pressure medications tainted with a known carcinogen have continued to expand, impacting tens of millions of patients in the United States. | 9/25/21 |
Counterfeit medicinesTournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea In 2012 a counterfeit of the cancer drug Avastin was found in the United States, entering the country through a complex worldwide “grey market” of suppliers. The counterfeit drugs traced a path through Turkey, Switzerland, the United Kingdom, and finally the United States,ending up in the hands of cancer patients fighting for their lives. Unbeknownst to the medical professionals prescribing what they thought were lifesaving prescriptions, the drugs were devoid of the active ingredient needed to reduce the growth of patients’ tumors.1The World Health Organization estimates that there are over 1 million deaths annually from counterfeit and substandard drugs, causing $21 billion global financial impacts. 2For the past 10 months, recalls of blood pressure medications tainted with a known carcinogen have continued to expand, impacting tens of millions of patients in the United States. | 9/25/21 |
Covid SubpointTournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas But what is even more important than what’s possible under a robust intellectual property system, is what’s impossible without it. First: continued research and development. It takes decades and often costs billions to bring a new medicine to market. The timeline for COVID-19 vaccine deployment in 2020 has been nothing short of miraculous – and it would have been impossible absent the decades of research investment it built upon. Additionally, for every 25,000 therapeutic compounds that start in the laboratory, 25 make it to clinical trial, 5 make it to market, and only one recoups the cost invested. Intellectual property protections signal to innovators and investors that shouldering this risk is worth it. Intellectual property protections promise that new ideas have tangible value. Without that signal and that promise, the business of innovation isn’t viable. Second: build-on innovation. The intellectual property system – specifically, the patent system – promotes the public disclosure of inventions, which encourages further discovery. When an innovator applies for a patent, they’re required to describe how their invention works and what it can do. The innovator’s discovery is respected for a period before transitioning into the public domain. That means, every time a patent is granted, the global innovation knowledge pool gets a little bigger. On the flip side, if countries quit respecting patents, the global innovation information pool dries up, knowledge contracts and the amount of private investment in RandD will inevitably shrink. Finally: A safe, legitimate marketplace. Patents facilitate a market for innovative medicines, throughout the development stage, as well as in commercialization. Licensing arrangements facilitate the types of collaborations that have proven so successful in 2020; they also ensure that third-party manufacturers are making, using, and selling COVID-19 solutions safely and ethically. Without it, counterfeiters and other bad actors could put shoddy, unreliable, and downright dangerous dupes on the market, all the while marketing them as legitimate products. It’s literally a matter of life and death: Thousands, if not millions, of people die each year at the hands of counterfeit drugs. | 9/25/21 |
Covid SubpointTournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea But what is even more important than what’s possible under a robust intellectual property system, is what’s impossible without it. First: continued research and development. It takes decades and often costs billions to bring a new medicine to market. The timeline for COVID-19 vaccine deployment in 2020 has been nothing short of miraculous – and it would have been impossible absent the decades of research investment it built upon. Additionally, for every 25,000 therapeutic compounds that start in the laboratory, 25 make it to clinical trial, 5 make it to market, and only one recoups the cost invested. Intellectual property protections signal to innovators and investors that shouldering this risk is worth it. Intellectual property protections promise that new ideas have tangible value. Without that signal and that promise, the business of innovation isn’t viable. Second: build-on innovation. The intellectual property system – specifically, the patent system – promotes the public disclosure of inventions, which encourages further discovery. When an innovator applies for a patent, they’re required to describe how their invention works and what it can do. The innovator’s discovery is respected for a period before transitioning into the public domain. That means, every time a patent is granted, the global innovation knowledge pool gets a little bigger. On the flip side, if countries quit respecting patents, the global innovation information pool dries up, knowledge contracts and the amount of private investment in RandD will inevitably shrink. Finally: A safe, legitimate marketplace. Patents facilitate a market for innovative medicines, throughout the development stage, as well as in commercialization. Licensing arrangements facilitate the types of collaborations that have proven so successful in 2020; they also ensure that third-party manufacturers are making, using, and selling COVID-19 solutions safely and ethically. Without it, counterfeiters and other bad actors could put shoddy, unreliable, and downright dangerous dupes on the market, all the while marketing them as legitimate products. It’s literally a matter of life and death: Thousands, if not millions, of people die each year at the hands of counterfeit drugs. | 9/25/21 |
Drug Manufacturing ChallengesTournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas Developing a new prescription medicine that gains marketing approval is estimated to cost drugmakers $2.6 billion according to a recent study by Tufts Center for the Study of Drug Development and published in the Journal of Health Economics. This is up from $802 million in 2003—equal to approximately $1 billion in 2013 dollars, and thus a 145 percent increase in the ten year study gap. Furthermore, while the average time it takes to bring a drug through clinical trials has decreased, the rate of success has gone down by almost half, to just 12 percent. | 9/25/21 |
Drug Manufacturing ChallengesTournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea Developing a new prescription medicine that gains marketing approval is estimated to cost drugmakers $2.6 billion according to a recent study by Tufts Center for the Study of Drug Development and published in the Journal of Health Economics. This is up from $802 million in 2003—equal to approximately $1 billion in 2013 dollars, and thus a 145 percent increase in the ten year study gap. Furthermore, while the average time it takes to bring a drug through clinical trials has decreased, the rate of success has gone down by almost half, to just 12 percent. | 9/25/21 |
IPR DefTournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas The definition of intellectual property rights is any and all rights associated with intangible assets owned by a person or company and protected against use without consent. Intangible assets refer to non-physical property, including right of ownership in intellectual property | 9/25/21 |
IPR DefTournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea The definition of intellectual property rights is any and all rights associated with intangible assets owned by a person or company and protected against use without consent. Intangible assets refer to non-physical property, including right of ownership in intellectual property | 9/25/21 |
IPR stopping CounterfeitsTournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas In addition to functioning as a tool to maintain constant innovation in the industry, IP helps reduce counterfeit medicines because medicines have better technologies and ingredients are more difficult to copy. This means that, through market incentives, the industry manages to have high quality infrastructure, new technology and trained personnel, to create specialized and specific medicines and therapies, which is why they are difficult to replicate. On the other hand, political will functions as another important axis, as it must prosecute those who are making counterfeit medicines. This is achieved through a constant conversation between industry and governments. Therefore, it will be absolutely clear how to identify the authenticity of medicines. In short, IP allows quality standards to be clearer and stricter, and regulators to have greater knowledge and traceability of each product that enters the market. Through IP, you can establish a record of all products globally, which makes it easier to find possible counterfeit medicines. | 9/25/21 |
IPR stopping CounterfeitsTournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea In addition to functioning as a tool to maintain constant innovation in the industry, IP helps reduce counterfeit medicines because medicines have better technologies and ingredients are more difficult to copy. This means that, through market incentives, the industry manages to have high quality infrastructure, new technology and trained personnel, to create specialized and specific medicines and therapies, which is why they are difficult to replicate. On the other hand, political will functions as another important axis, as it must prosecute those who are making counterfeit medicines. This is achieved through a constant conversation between industry and governments. Therefore, it will be absolutely clear how to identify the authenticity of medicines. In short, IP allows quality standards to be clearer and stricter, and regulators to have greater knowledge and traceability of each product that enters the market. Through IP, you can establish a record of all products globally, which makes it easier to find possible counterfeit medicines. | 9/25/21 |
Open Source
| Filename | Date | Uploaded By | Delete |
|---|---|---|---|
10/2/21 | giesesawye24@cpsk12arus |
| |
9/25/21 | giesesawye24@cpsk12arus |
| |
9/25/21 | giesesawye24@cpsk12arus |
|